This study is for adults with pancreatic cancer, a disease where cells grow uncontrollably in the pancreas. The study will test a new drug, *telisotuzumab adizutecan*, combined with other cancer drugs (called FOLFOX), against standard treatment. **Participants** will be split into groups to receive different treatments over approximately 6 years. Phase 2 of the study will determine the best dose of the new drug. Phase 3 will test this dose against standard treatment. Participants must have pancreatic cancer that cannot be removed by surgery and should not have received certain previous treatments. They will have regular doctor visits, blood tests, and answer questions about their health. The study will happen in about 200 places worldwide with around 900 participants.
Key Points:- The study lasts approximately 6 years and involves regular medical visits.
- Participants must have certain types of pancreatic cancer and meet specific health criteria.
- Participants will receive either new drug treatment or standard care.